Company intelligence / Profile preview

Alphyn Biologics

Annapolis, Maryland, USAalphynbiologics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company’s lead asset, Zabalafin Hydrogel (AB‑101a), has completed two Phase 2a clinical trials in atopic dermatitis—both cohorts met all primary and secondary endpoints. Results showed significant improvements in itch reduction, quality of life, inflammation control, clearance of infected AD skin, and control of staph-associated flares. The product demonstrated minimal side effects and excellent tolerability. A global Phase 2b trial began dosing patients in April 2025.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Multi-target therapeutics (botanical drug with multiple bioactive compounds)topical hydrogel formulationsmall molecules (inferred from botanical origin and multi-bioactive approach)
Industry: Biotech

Drug pipeline

1 asset

zabalafin

Beyond the preview

Go deeper on Alphyn Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alphyn Biologics.

Explore the full profile